Claudin-1 expression is elevated in colorectal cancer precursor lesions harboring the BRAF v600e mutation

Translational Oncology

Volumn 7, Issue 4, 2014, Pages 456-463

  Caruso, Maria ^a   Fung, Kim Y C ^b   Moore, James ^c,e   Brierley, Gemma V ^b   Cosgrove, Leah J ^b   Thomas, Michelle ^c,e   Cheetham, Glenice ^d   Brook, Emma ^e   Fraser, Louise M ^e   Tin, Teresa ^a   Tran, Ha ^a   Ruszkiewicz, Andrew ^a,e,f  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b CSIRO   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d Molecular Pathology   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f Genetics and Molecular Pathology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CLAUDIN 1; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL POLYP; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MICROVESICULAR HYPERPLASTIC POLYP; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; RECTUM ADENOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; VERY ELDERLY;

EID: 84907313069     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.05.009     Document Type: Article

References (51)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, and Bos JL (1988). Genetic alterations during colorectal-tumor development. N Engl J Med 319, 525-532.
2. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ, and Kalady MF, et al (2012). Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 107, 1315-1329[quiz 1314, 1330].
3. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, and Nesland JM (2003). Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 27, 65-81.
4. Bettington M, Walker N, Clouston A, Brown I, Leggett B, and Whitehall V (2013). The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 62, 367-386.
5. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, and Buchanan D, et al (2006). CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38, 787-793.
6. Fearon ER and Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
7. Burnett-Hartman AN, Newcomb PA, Potter JD, Passarelli MN, Phipps AI, Wurscher MA, Grady WM, Zhu LC, Upton MP, and Makar KW (2013). Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 73, 2863-2872.
8. Sentani K, Sakamoto N, Shimamoto F, Anami K, Oue N, and Yasui W (2013). Expression of olfactomedin 4 and claudin-18 in serrated neoplasia of the colorectum: a characteristic pattern is associated with sessile serrated lesion. Histopathology 62, 1018-1027.
9. Caruso M, Moore J, Goodall GJ, Thomas M, Phillis S, Tyskin A, Cheetham G, Lerda N, Takahashi H, and Ruszkiewicz A (2009). Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis. Virchows Arch 454, 291-302.
10. Gonzalo DH, Lai KK, Shadrach B, Goldblum JR, Bennett AE, Downs-Kelly E, Liu X, Henricks W, Patil DT, and Carver P, et al (2013). Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol 230, 420-429.
11. Conesa-Zamora P, García-Solano J, García-García F, Turpin Mdel C, Trujillo- Santos J, Torres-Moreno D, Oviedo-Ramírez I, Carbonell-Muñoz R, Muñoz-Delgado E, and Rodriguez-Braun E, et al (2013). Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. Int J Cancer 132, 297-307.
12. Joyce T, Oikonomou E, Kosmidou V, Makrodouli E, Bantounas I, Avlonitis S, Zografos G, and Pintzas A (2012). A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis. Curr Cancer Drug Targets 12, 873-898.
13. Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, Karttunen TJ, Tuppurainen K, and Davalos V, et al (2007). Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 26, 312-320.
14. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, and Kurzrock R (2011). BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 6, e25806.
15. Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M, and Church JM (2012). BRAFmutations in colorectal cancer are associatedwith distinct clinical characteristics and worse prognosis. Dis Colon Rectum 55, 128-133.
16. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, and Shadrach B, et al (2012). BRAF-mutated, microsatellitestable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 36, 744-752.
17. Goldstein NS (2006). Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol 125, 132-145.
18. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Tomino Y, Oda J, Mizutani M, Takayanagi S, and Kishi D, et al (2009). Progression of a sessile serrated adenoma to an early invasive cancer within 8 months. Dig Dis Sci 54, 906-909.
19. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, and Tuech JJ, et al (2007). Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96, 1166-1169.
20. Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57, 289-300.
21. Jass JR (1983). Relation between metaplastic polyp and carcinoma of the colorectum. Lancet 1, 28-30.
22. Jass JR, Iino H, Ruszkiewicz A, Painter D, Solomon MJ, Koorey DJ, Cohn D, Furlong KL, Walsh MD, and Palazzo J, et al (2000). Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut 47, 43-49.
23. Chan TL, Zhao W, Leung SY, and Yuen ST (2003). BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63, 4878-4881.
24. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, Barker MA, Arnold S, McGivern A, and Matsubara N, et al (2004). BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53, 1137-1144.
25. Kim KM, Lee EJ, Kim YH, Chang DK, and Odze RD (2010). KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. Am J Surg Pathol 34, 667-675.
26. Yang S, Farraye FA, Mack C, Posnik O, and O'Brien MJ (2004). BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28, 1452-1459.
27. Mesteri I, Bayer G, Meyer J, Capper D, Schoppmann SF, von Deimling A, and Birner P (2014). Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mod Pathol 27, 135-144.
28. Iino H, Jass JR, Simms LA, Young J, Leggett B, Ajioka Y, and Watanabe H (1999). DNAmicrosatellite instability in hyperplastic polyps, serrated adenomas, andmixed polyps: a mild mutator pathway for colorectal cancer? J Clin Pathol 52, 5-9.
29. Issa JP (2004). CpG island methylator phenotype in cancer. Nat Rev Cancer 4, 988-993.
30. O'Brien MJ, Yang S, Clebanoff JL, Mulcahy E, Farraye FA, Amorosino M, and Swan N (2004). Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol 28, 423-434.
31. Garcia-Solano J, Conesa-Zamora P, Carbonell P, Trujillo-Santos J, Torres-Moreno DD, Pagan-Gomez I, Rodriguez-Braun E, and Perez-Guillermo M (2012). Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. Int J Cancer 131, 1790-1799.
32. de Oliveira SS, de Oliveira IM, De Souza W, and Morgado-Diaz JA (2005). Claudins upregulation in human colorectal cancer. FEBS Lett 579, 6179-6185.
33. Gröne J, Weber B, Staub E, Heinze M, Klaman I, Pilarsky C, Hermann K, Castanos-Velez E, Röpcke S, and Mann B, et al (2007). Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1, -8 and -12. Int J Colorectal Dis 22, 651-659.
34. Kinugasa T, Huo Q, Higashi D, Shibaguchi H, Kuroki M, Tanaka T, Futami K, Yamashita Y, Hachimine K, and Maekawa S, et al (2007). Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer. Anticancer Res 27, 3729-3734.
35. Bezdekova M, Brychtova S, Sedlakova E, Langova K, Brychta T, and Belej K (2012). Analysis of snail-1, e-cadherin and claudin-1 expression in colorectal adenomas and carcinomas. Int J Mol Sci 13, 1632-1643.
36. Ersoz S, Mungan S, Cobanoglu U, Turgutalp H, and Ozoran Y (2011). Prognostic importance of Claudin-1 and Claudin-4 expression in colon carcinomas. Pathol Res Pract 207, 285-289.
37. Nakagawa S, Miyoshi N, Ishii H, Mimori K, Tanaka F, Sekimoto M, Doki Y, and Mori M (2011). Expression of CLDN1 in colorectal cancer: a novel marker for prognosis. Int J Oncol 39, 791-796.
38. Resnick MB, Konkin T, Routhier J, Sabo E, and Pricolo VE (2005). Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18, 511-518.
39. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, and Beauchamp RD (2005). Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115, 1765-1776.
40. Singh AB, Sharma A, and Dhawan P (2012). Claudin-1 expression confers resistance to anoikis in colon cancer cells in a Src-dependent manner. Carcinogenesis 33, 2538-2547.
41. Endo A, Koizumi H, Takahashi M, Tamura T, Tatsunami S, Watanabe Y, and Takagi M (2013). A significant imbalance in mitosis versus apoptosis accelerates the growth rate of sessile serrated adenoma/polyps. Virchows Arch 462, 131-139.
42. Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG, Fukamachi H, and Ito Y (2010). Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 138(255-265), e251-e253.
43. Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, and Wang H, et al (2008). RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14, 226-237.
44. Li L, Fu X, Zhang W, Xiao L, Qiu Y, Peng Y, Shi L, Chen X, Zhou X, and Deng M (2013). Wnt signaling pathway is activated in right colon serrated polyps correlating to specific molecular form of β-catenin. Hum Pathol 44, 1079-1088.
45. Wu JM, Montgomery EA, and Iacobuzio-Donahue CA (2008). Frequent betacatenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential. Am J Clin Pathol 129, 416-423.
46. Yachida S, Mudali S, Martin SA, Montgomery EA, and Iacobuzio-Donahue CA (2009). Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol 33, 1823-1832.
47. Fu X, Yang X, Chen K, and Zhang Y (2011). Retained cell-cell adhesion in serrated neoplastic pathway as opposed to conventional colorectal adenomas. J Histochem Cytochem 59, 158-166.
48. Fujita K, Yamamoto H, Matsumoto T, Hirahashi M, Gushima M, Kishimoto J, Nishiyama K, Taguchi T, Yao T, and Oda Y (2011). Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am J Surg Pathol 35, 295-304.
49. Pai RK, Mojtahed A, Rouse RV, Soetikno RM, Kaltenbach T, Ma L, Arber DA, Plesec TP, and Goldblum JR (2011). Histologic and molecular analyses of colonic perineurial-like proliferations in serrated polyps: perineurial-like stromal proliferations are seen in sessile serrated adenomas. Am J Surg Pathol 35, 1373-1380.
50. Hornick JL and Fletcher CD (2005). Intestinal perineuriomas: clinicopathologic definition of a new anatomic subset in a series of 10 cases. Am J Surg Pathol 29, 859-865.
51. Groisman GM and Polak-Charcon S (2008). Fibroblastic polyp of the colon and colonic perineurioma: 2 names for a single entity? Am J Surg Pathol 32, 1088-1094.